摘要
Background aims: The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL) patients, particularly those treated with rituximab for a short time. This prospective study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL patients previously treated with rituximab. @@@ Methods: The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021. @@@ Results: An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome. @@@ Conclusions: All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.
学科与关键词
- Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patientsQu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
- Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphomaZhang, Ying; Geng, Hongzhi; Zeng, Liangyu; Li, Jiaqi; Yang, Qin; Jia, Sixun; Zong, Xiangping; Cai, Wenzhi; Liu, Shuangzhu; Lu, Yutong; Yu, Lei; Li, Caixia*; Wu, Depei*Hematological Oncology, 2023.
- CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System LymphomaLiu, Rui; Cheng, Qian; Kang, Liqing; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Zhang, Yi; Chu, Ling; Chen, Xin; Zhang, Chang; Tan, Jingwen; Xu, Nan; Li, Minghao; Yu, Lei; Li, Xin*Human Gene Therapy, 2022, 33(5-6): 318-329.被引 9
